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derived compounds that are present in the human diet and are considered selective
estrogen receptor (ER) modulators. The phytoestrogen coumestrol is a potent isoflavonoid,
with binding affinities for both ER-a and ER-b that are comparable to those of 17b-estradiol.
The present study examined the hypothesis that coumestrol protects hippocampal
neurons in ovariectomized rats in a model of cerebral global ischemia. Ovariectomized
rats were subjected to global ischemia (10 min) or sham surgery and received a single
intracerebroventricular or peripheral infusion of 20 mg of coumestrol, 20 mg of estradiol or
vehicle 1 h before ischemia or 0 h, 3 h, 6 h or 24 h after reperfusion. Estradiol and
coumestrol afforded significant neuroprotection in all times of administration, with the
exception of estradiol given 24 h after the ischemic insult. Animals received icv infusion of
the broad-spectrum ER antagonist ICI 182,780 (50 mg) or vehicle into the lateral ventricle
just before the E2 or coumestrol administration. The ER antagonist abolished estradiol
protection, consistent with a role of classical ERs. In contrast, ICI 182,780 effected only
partial reversal of the neuroprotective actions of coumestrol, suggesting that other cellular
mediators in addition to classical ERs may be important. Additional research is needed to
determine the molecular targets mediating the neuroprotective action of coumestrol and
the therapeutic potential of this phytoestrogen in the mature nervous system.
& 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Stroke is the third leading cause of death in industrialized
countries (Lewis et al., 2008) and the most frequent cause ofthe Elsevier OA license.
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. Canal Castro).permanent disability in adults worldwide (Donnan et al.,
2008). Three months following a stroke, 15–30% of stroke
survivors are permanently disabled and 20% require institu-
tional care. Deficits can include partial paralysis, difficulties
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western world, over 70% of individuals experiencing a stroke
are over 65 years of age. Since life expectancy continues to
grow, the absolute number of individuals with stroke will
further increase in the future (Lakhan et al., 2009). Transient
global ischemia arises as a consequence of cardiac arrest
and causes selective, delayed death of hippocampal CA1
neurons in humans and can produce serious neurobiological
sequellae of which cognitive deficits are most prominent
(Lo et al., 2003; Moskowitz et al., 2010; Tanaka et al., 2000;
Merchenthaler et al., 2003; Etgen et al., 2010).
Over the last decade, data from many studies support the
idea that estrogens provide neuroprotective effects in a
variety of focal and global ischemia models (Lebesgue et al.,
2009; Merchenthaler et al., 2003; Garcia-Segura et al., 2001;
Toran-Allerand, 2004; Shughrue and Merchenthaler, 2003).
The potent feminizing hormone, 17 beta-estradiol (E2), is
neuroprotective in a host of cell and animal models of stroke
and neurodegenerative diseases. The discovery that 17 alpha-
estradiol, an isomer of E2, is equally as neuroprotective as E2
yet is 4200-fold less active as a hormone, has permitted
development of novel, more potent analogs where neuropro-
tection is independent of hormonal potency (Simpkins and
Dykens, 2008). For example, a single dose of estradiol admi-
nistered immediately after reperfusion (acute estradiol) ame-
liorates global ischemia-induced neuronal death and
cognitive deficits (Jover-Mengual et al., 2010; Gulinello et al.,
2006). Moreover, a single injection of 17 b-estradiol adminis-
tered to ovariectomized rats 2–4 day before ischemia also
protects hippocampal neurons against ischemic damage via
activation of CREB (Raval et al., 2009). At physiological con-
centrations it intervenes in apoptotic death cascades and
ameliorates neuronal death in experimental models of focal
and global ischemia (Brown et al., 2009; Gill et al., 2002;Fig. 1 – Photomicrographs (40X) of the hippocampal CA1 region
after reperfusion. Rats that underwent global ischemia had sign
groups (po0,01). Estradiol and Coumestrol treatment afforded rLebesgue et al., 2009). The cellular targets that mediate
estradiol protection of hippocampal neurons in global ische-
mia are, however, unclear (Miller et al., 2005; Etgen et al.,
2010; Strom et al., 2009; Brown et al., 2009; Suzuki et al., 2009;
Yang et al., 2003; Barrera-Ocampo et al., 2008; Alonso de
Lecin˜ana and Egido, 2006).
Phytoestrogens are estrogen-like molecules found in
many plants. They have the ability to selectively bind
classical estrogen receptors (ERs) to regulate gene expression
mediated by estrogen response elements (Zhao et al., 2002).
Phytoestrogens have been investigated intensively in recent
years because of their potential protective effects against
many diseases (Lephart et al., 2000). They not only bind to ERs
but also exert potent antioxidant activity. It is increasingly
clear that physiologically attainable doses of isoflavones,
which can behave as phytoestrogens, may mimic some of
the neuroprotective effects of estrogens. Some phytoestro-
gens exhibit some estrogen agonist-like properties (Stahl
et al., 1998 and Ma¨kela¨ et al., 1995). Zhao et al., 2002 reported
a significant reduction in glutamate-induced lactate dehy-
drogenase release and subsequently neuroprotection by phy-
toestrogens such as genistein, daidzein, daidzin, equol and
formonoetin in cultured hippocampal neurons. A high soy
diet reduces stroke injury in female and male rats, and the
soy isoflavone genistein is neuroprotective in a mouse cere-
bral ischemia model (Donzelli et al., 2010). Moreover, dietary
intake of phytoestrogens can improve outcomes after focal
(Lovekamp-Swan et al., 2007; Burguete et al., 2006) and global
ischemia in rats (Liang et al., 2008). However, the mechan-
isms underlying protection from ischemic injury remain
unclear (Schreihofer and Redmond, 2009).
Among the hundreds of molecules that fall under this
classification, the coumestan phytoestrogen coumestrol (derived
from sprouting plants like alfalfa), has gained prominenceof female rats with or without 10-min global ischemia 7 day
ificantly fewer surviving neurons than the sham-operated
obust neuroprotection. Scale bar¼100 lm.
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nities for both ER-a and ER-b that are comparable to those of 17
b-estradiol (Whitten et al., 2002). As ERs are expressed in several
regions of the brain that are vulnerable to ischemia-induced
neuronal death, we sought to determine whether the coumes-
trol has neuroprotective actions in CA1 hippocampal cells
and whether its effects are mediated through classical ERs.
If so, it could be a potential therapeutic treatment for global
brain ischemia.Fig. 2 – Effect of the treatment of coumestrol and estradiol in
different times of administration. Ovarectomized female
rats were subjected to global ischemia (10 min) or sham
surgery and received a single icv infusion of 20 lg of
coumestrol or 20 lg of estradiol or vehicle 1 h before
ischemia or 0 h, 3 h, 6 h and 24 h after reperfusion. The
ischemic groups had less surviving neurons in comparison
with the sham groups. Estradiol and coumestrol afforded
significant neuroprotection in all times of administration,
with the exception of estradiol in 24 h after the ischemic
insult. (a) Difference between ischemic and sham groups;
(b) difference between ischemic treated groups and vehicle,
with the exception of estradiol in 24 h after ischemia. Each
bar represents the mean7standard error of the mean (SEM).
ANOVA followed by Duncan’s test, po0.01.2. Results
Ovarectomized female rats were subjected to global ischemia
or sham operation and recovered from an icv infusion of
estradiol, coumestrol in vehicle or vehicle alone in different
times. Global ischemia induced extensive death of pyramidal
cells in the CA1 subfield of hippocampus accessed at 7 day
post-ischemia (po0.01 vs. sham) (Fig. 1d). Estradiol did not
detectably alter the appearance or number of CA1 neurons in
sham-operated rats (Fig. 1b), but greatly reduced the ische-
mia-induced neuronal loss (po0.01 vs. ischemia), (Fig. 1e).
As expected, coumestrol did not detectably alter the appear-
ance or number of CA1 neurons in sham-operated rats
(Fig. 1c), and also greatly reduced the ischemia-induced
neuronal loss (po0.01 vs. ischemia) (Fig. 1f). There were no
significative difference between the estradiol and coumestrol
groups at 1 h before, 0 h, 3 h and 6 h after ischemia-induced
neuronal loss, but at 24 h, the statistical analysis detected a
significative difference between these two groups (po0.01 vs.
ischemia) (Fig. 2), providing a clear evidence of neuroprotec-
tion promoted by coumestrol. The ER antagonist ICI 182,780,
when administered at 0 h after surgery, did not detectably
alter the number or appearance of surviving neurons in
sham-operated rats or vehicle-treated animals subjected to
ischemia, but totally abrogated the neuroprotective action of
estradiol in the hippocampal CA1 layer (po0.01 vs. estradiol
alone) and partially blocked the neuroprotection afforded by
coumestrol at 0 h post-ischemia (po0.01 vs. coumestrol
alone). Moreover, the statistical comparison showed a sig-
nificative difference between the ischemic groups coumestrol
and estradiol (po0.01) indicating that whereas the antagonist
ICI 182,780 reverses the estradiol neuroprotection, it was not
totally able to reverse the neuroprotective actions of coumes-
trol, thus providing strong evidence that this compound is
more effective in promoting neuronal survival than estradiol
itself (Fig. 3). To access if coumestrol administration could be
neuroprotective when administered peripherally as well we
injected a single dose of 20 mg/kg intracardiaclly one hour
before the global ischemia. The peripheral administration of
coumestrol strongly prevented the delayed neuronal death
after global ischemia (Fig. 4). Global ischemia induced exten-
sive death of pyramidal cells in the CA1 subfield of hippo-
campus accessed at 7 day post-ischemia (po0.01 vs. sham)
(Fig. 5). We did not detect any changes in the number of cells
in the CA1 subfield in sham-operated rats in comparison with
the coumestrol sham-operated rats (Fig. 4). The statistical
comparison showed a significative difference between the
ischemic group and coumestrol (po0.01) indicating thatcoumestrol was able to afford robust neuroprotection in the
ischemic rats (po0.01 vs. ischemia) (Fig. 5).3. Discussion
Estradiol and estrogen-like compounds are powerful neuro-
protective agents against numerous in vivo and in vitro
apoptotic stimuli including experimental stroke (Hurn and
Brass, 2003; McCullough and Hurn, 2003; Alonso de Lecin˜ana
and Egido, 2006; Gibson et al., 2006). However, the precise
mechanisms underlying these protective effects are still
under investigation.
It is now well established in the literature that endogenous
and exogenous estrogens exert profound neuroprotective
effects in animal models of focal and global ischemia and
produce their cellular actions by binding the classical estro-
gens receptors. Thus, estrogens hold great promise as
Fig. 3 – Effect of the ER antagonist ICI 182,780 treatment 0 h
after ischemia. All groups were treated with estradiol or
coumestrol (20 lg icv) and undergone to ischemia or sham
surgery. The ER antagonist ICI 182,780 treatment fully
abolished the neuroprotection promoted by estradiol but
partially abrogated the coumestrol neuroprotection effect.
Treatment with the ER antagonist did not affect the number
of surviving neurons in any of the other treatment groups;
therefore, for the statistical analysis, sham-operated vehicle
and ICI 182,780 treated groups were combined. (a)
Difference between sham and ischemic groups; (b)
difference between the ischemic treated coumestrol and
vehicle groups; (c) difference between the ischemic
coumestrol and estradiol treated groups. Each bar
represents the mean7standard error of the mean (SEM).
ANOVA followed by Duncan’s test, po0.01.
Fig. 4 – Photomicrographs (40X) of the hippocampal CA1
region of female rats with or without 10-min global
ischemia 7 day after reperfusion. Rats that underwent
global ischemia had significantly fewer surviving neurons
than the sham-operated groups (po0.01). The peripheric
pre-treatment of coumestrol strongly protected the CA1
hippocampal layer. Scale bar¼100 lm.
Fig. 5 – Effect of the peripheric administration of coumestrol
one hour before global ischemia. Ovarectomized female rats
were subjected to global ischemia (10 min) or sham surgery
and received a single intracardiac infusion of 20 lg of
coumestrol or vehicle 1 h before ischemia. The ischemic
groups had less surviving neurons in comparison with the
sham groups. Coumestrol afforded significant
neuroprotection in (a) difference between ischemic and
sham groups; (b) difference between ischemic vehicle group
and coumestrol group. Each bar represents the
mean7standard error of the mean (SEM). ANOVA followed
by Duncan’s test, po0.01.
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et al., 2010). Along with phytoestrogens, the coumestan
coumestrol, which is present in sprout of soybeans, clover
and alfalfa, is another significant phytoestrogens regularly
consumed by humans (Belcher and Zsarnovszky, 2001). This
compound is known to be the most potent isoflavonoid, with
binding affinities for both ERs that are comparable to those of
17 b-estradiol (Whitten et al., 2002).
Our results show that coumestrol, at all time of adminis-
trations, injected icv or intracardiaclly, protected neurons
against global ischemia-induced CA1 neuronal death, indi-
cating that this compound may work against the cascade of
pathological events that lead to neuronal death. Both estra-
diol and coumestrol were able to promote neuroprotection in
a cerebral global ischemia model when administered 1 h
before and 0 h, 3 h and 6 h after ischemia. However, estradiol
at 24 h after the ischemic event was not effective in prevent-
ing massive neuronal death at the hippocampal layer. It is
interesting to note that coumestrol, at this same time of
administration, was able to prevent the neuronal death
promoted by the global ischemia. There are a few reports in
the literature showing treatments that are still effective when
delayed 24 h after ischemia. The two most cited long term
strategies to the treatment of global ischemia is hypothermia
(Tooley et al., 2002; Colbourne et al., 2000; Corbett et al., 2000;Colbourne and Corbett, 1994; Valentim et al., 2003) and
preconditioning (Zhang et al., 2010; Yoshida et al., 2004;
Boche et al., 2003; Dowden and Corbett, 1999). The mechan-
isms of coumestrol-mediated neuronal protection have not
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gen receptor and non-receptor actions.
In order to further ascertain whether coumestrol could be a
tangible therapeutic strategy against global ischemia injury,
we injected intracardiaclly a single dose of 20 mg/kg of
coumestrol one hour before the global ischemia. For our
surprise, the peripheric administration appears to be even
more neuroprotective in comparison with the icv adminis-
tration (statistical analysis not shown). It is well documented
that systemic administration of pharmacological doses of
estradiol can be neuroprotective in global ischemia (Lebesgue
et al., 2010) and in focal ischemia (Fan et al., 2003). We
presume that coumestrol can reach similar brain levels as
much as estradiol since both are small molecules that are
highly lipophilic therefore, they cross the Blood Brain Barrier
and cell membranes easily.
The mechanisms by which coumestrol is acting either icv
or peripherally to afford robust neuroprotection remain
unclear. Its protective effects appear to be receptor-
mediated since its beneficial effect in histological para-
meter was partially prevented by the broad-spectrum ER
antagonist ICI 182,780. ERs play a critical role in the
neuroprotective effects of phytoestrogens (Schreihofer
and Redmond, 2009). Coumestrol has a relative binding
affinity for ER-b approximately equivalent to 17 b-estradiol
(Kuiper et al., 1998). Both ERs are expressed in the rodent
hippocampus but ER-b is more prevalent regulating hippo-
campal synaptic plasticity (Mitra et al., 2003) and improving
neuronal survival. Increased ER-b immunoreactivity in the
post-ischemic monkey hippocampus has also been found
(Takahashi et al., 2004).
There are several lines of evidence that ER-b is involved in
neuroprotection (Sawada et al., 1998). Comparison of relative
binding affinities from various studies indicates that some
phytoestrogens appear to have a higher affinity for ER-b than
for ER-a and therefore suggests that the ER-mediated effects
of phytoestrogens may be mediated through ER-b (Belcher
and Zsarnovszky, 2001). However, is still unclear which ER
subtype mediates the neuroprotective efficacy of estrogen/
phytoestrogen.
The icv and the peripheral administration of coumestrol in
different times before and after ischemia and the partial
neuroprotection abrogation by the ER antagonist indicate that
the neuroprotection afforded by this compound likely
involves activation of the classical ERs. However, this not
rules out the possibility that other estrogen receptors or
pathways of neuronal survival may play a role in coumestrol
neuroprotection following ischemic insult. The partial abro-
gation by the antagonist suggest that it might be another
alternative pathway that coumestrol is using to reach neu-
roprotection to CA1 than just through the ER pathway.
Furthermore, some neuroprotective effects of estrogen-like
compounds appear to be independent of their ability to bind
ERs (Prokai and Simpkins, 2007).
Studies conducted with other phytoestrogens affording
neuroprotection in models of cerebral ischemia and other
neurodegenerative diseases agree with our findings (Al-
Nakkash et al., 2009; Donzelli et al., 2010; Kim et al., 2009;
Carswell et al., 2004). Genistein (Kindy, 1993; Donzelli et al.,
2010), (-) catechin (Inanami et al., 1998), green tea extractsrich in phytoestrogens (Hong et al., 2001) have been shown to
limit brain injury in gerbil model of global cerebral ischemia.
In a study conducted by Schreihofer (2005) genistein demon-
strated to protect neurons from transient global ischemia
injury in rat hippocampus by attenuating oxidative stress,
lipid peroxidation, and the signaling cascade leading to
apoptotic cell death.
Recent evidence indicates that the production of reactive
oxygen species (ROS) such as superoxide radicals, hydroxyl
radicals and hydrogen peroxide is increased after cerebral
ischemia. Since the rates of oxidative metabolic activities are
high and the antioxidants enzyme activities are low in the
brain, neurons are vulnerable to ischemic events. In studies
about phytoestrogen antioxidant proprieties, coumestrol
showed a high hydrogen/electron donation via hydroxyl
groups and demonstrated to have an effective antioxidant
activity (Mitchell et al., 1998). It is well know that phytoestro-
gens, acting as antioxidants, can decrease the accumulation
of ROS, thereby protecting cell membrane integrity and so
promoting neuronal survival (Cai et al., 1997; Mitchell et al.,
1998). However, the ROS production after the ischemic insult
remains for a very short period in the cell (Thiyagarajan et al.,
2004; Golden and Patel, 2009; Kleinschnitz et al., 2010)
suggesting that perhaps the neuroprotection seeing after
24 h or even after 6 h afforded by coumestrol administration
may be not due its antioxidant proprieties. The mechanism,
however, by which coumestrol was neuroprotective against
delayed neuronal death has not been fully elucidated. Further
studies are necessary to elucidate other molecular targets
mediating the action of the coumestrol.
Beyond chemical antioxidant proprieties, other biochem-
ical mechanisms might also play a role in neuronal survi-
val. It is now clear that estrogens initiate rapid signaling
events in neurons by binding to recognition molecules
other than the classical receptors ER-a and ER-b. Recent
studies reveal the existence of transmembrane receptors
capable of responding to steroids with cellular activation.
On such receptor, GPR30, is a member of the G protein
coupled receptor superfamily and mediates transcription-
dependent and independent actions of estrogens and
widely expressed in the brain including hippocampus
(Filardo et al., 2002; Filardo and Thomas, 2005); Prossnitz
et al., 2007, 2008). Estradiol exhibits an affinity for GPR30
similar to ER-a and ER-b (Etgen et al., 2010) and its binding
to GPR30 stimulates production of cAMP, mobilization of
calcium and activation of growth factor signaling (Prossnitz
et al., 2007, 2008; Filardo et al., 2000, 2002). There is strong
evidence that GPR30 can act together with intracellular ERs
to activate cell signaling pathways to promote neuronal
survival after global ischemia (Lebesgue et al., 2009). There-
fore this might be an alternative pathway of neuronal
survival afforded by coumestrol in cerebral global ischemia.
Additional studies are needed to verify the molecular
mechanisms involving this receptor and its targets in
neuroprotection. Determining whether ERs and/or other
membrane estrogen receptors mediate estradiol and cou-
mestrol neuroprotection following global ischemia is of
great interest both for the development of therapeutic
strategies and for elucidating underlying molecular
mechanisms of delayed neuronal death.
b r a i n r e s e a r c h 1 4 7 4 ( 2 0 1 2 ) 8 2 – 9 0 87In conclusion, with the present study we have demon-
strated that coumestrol prevented long-term neuronal death
in CA1 hippocampal layer in rats when submitted to 10 min
global ischemia. Such findings suggest that this compound
interferes with the early and delayed stages of neuronal
damage. Furthermore, our study reports the first evidence
that an acute administration of coumestrol significantly
reduces the delayed neuronal cell death occurring in hippo-
campus of female rats following a transient global ischemic
insult. The mechanisms underlying the neuroprotection
exerted by coumestrol seem to involve, at least in part,
estrogen receptor activation, antioxidant activity and activa-
tion of other membrane receptors that mediate estradiol
neuroprotection. Additional studies are needed to determine
the molecular targets mediating the neuroprotective action of
coumestrol and the effects that this phytoestrogen may have
on the mature nervous system.4. Experimental procedure
4.1. Animals
Female adult Wistar rats (3 months, 170–210 g BW) were
obtained from the Central Animal House of the Department
of Biochemistry, Instituto de Cieˆncias Ba´sicas da Sau´de,
Universidade Federal do Rio Grande do Sul, Porto Alegre, RS,
Brazil. Animals were maintained on a 12/12 h light/dark cycle
in an air-conditioned constant temperature (2271 1C) colony
room, with free access to water. This work was carried out in
accordance with the EC directive 86/609/EEC for animal
experiments. The study was approved by the Ethics Commit-
tee of the Universidade Federal do Rio Grande do Sul, Brazil.
4.2. Surgery
Rats weighing between 150 and 250 g at time of surgery were
ovariectomized (OVX) by the surgical removal of both ovaries
under intraperitoneal (i.p.) ketamine anesthesia (90 mg/kg)
and xylazine (10 mg/kg) to eliminate endogenous ovarian
steroids (Waynforth and Flecknell, 1992).
4.3. Groups
The animals were randomized into six groups: Vehicle-
treated sham and ischemic; coumestrol-treated sham and
ischemic; 17 b-estradiol-treated sham and ischemic (used as
positive control). For the broad-spectrum ER antagonist ICI
182,780 experiment, the same groups were used (n¼5 ani-
mals/group).
4.4. Global ischemia
One week following the OVX surgery, rats was subjected to
transient global ischemia by four vessel occlusion as pre-
viously described by Pulsinelli and Brierley (1979). Rats were
deeply anesthetized under halothane (4% induction, 1%
maintence in 70% N2O:30% O2), and the vertebral arteries
were irreversibly occluded by electrocoagulation to prevent
collateral blood flow to the forebrain during the subsequentocclusion of the common carotid arteries. A silk thread was
looped around the carotid arteries to facilitate subsequent
occlusion. Twenty-four hours later, the animals were
anesthetized again, the wound was reopened and both
carotid arteries were occluded with micro arterial clamps
for 10 min. The 4 VO model were chosen because it is the
most used model that resembles a human cardiac arrest
where the blood supply in the brain is almost depleted. The
outcomes are neurological damage, loss of memory, convul-
sions and coma. During clamping, the animals were awake
and spontaneously ventilating. During both surgeries, rectal
temperature was monitored and maintained at 36.5–37.5 1C
with a rectal thermistor and heat lamp until recovery from
anesthesia. Sham operated animals were subjected to the
same anesthesia and surgical procedures as animals sub-
jected to global ischemia, except the carotid arteries were not
occluded (Netto et al., 1993). Animals that failed to show
complete loss of the righting reflex and pupillary dilatation
(from 2 min after occlusion has initiated until the end of
occlusion); animals that exhibited obvious behavioral mani-
festations (abnormal vocalization when handled, convul-
sions, hyperactivity etc.) were excluded from the
experiment; and animals with loss of greater than 20% of
body weight by 3–7 day after ischemia. There were 5 deaths
due to respiratory arrest; 11 other rats were excluded from
the study because they failed to show neurological signs of
ischemia (no loss of consciousness or incomplete dilation of
the pupils during occlusion).
4.5. Drugs
One hour before ischemia or 0 h, 3 h, 6 h or 24 h after
ischemia animals received intracerebroventricular (icv) injec-
tions into the right lateral ventricle of 20 mg of coumestrol
(Sigma) (diluted in 100% dimethylsufoxide) (DMSO; Sigma),
20 mg of 17 b-estradiol (diluted in 0.9% saline solution contain-
ing 10% DMSO) or 50 mg of ICI 182,780 (Sigma), in a volume of
2 ml. Control animals were infused with vehicle (100% DMSO).
The dose of 20 mg was chosen based on previous studies with
estrogen-like compounds (Azcoitia et al., 1999;Picazo et al.,
2003; Callier et al., 2001; Bryant et al., 2005; Toung et al., 2000)
with similar proprieties and actions in the central nervous
system. Animals also received icv infusion of the broad-
spectrum antagonist ICI 182,780 or vehicle into the lateral
ventricle. The administration of 50 mg was done 10 min prior
to the other drugs administration. For the peripheral admin-
istration, a dose of 20 mg/kg of coumestrol was injected
intracardiaclly one hour before the ischemic insult. Coumes-
trol was diluted in 100% dimethylsufoxide (DMSO; sigma) in a
volume of 300 ml.
4.6. Intracerebroventricular and peripheral injections
In the first experiment, rats were positioned in a stereotaxic
apparatus and icv injections performed under halothane
anesthesia either 1 h before ischemia or 0 h, 3 h, 6 h or 24 h
after ischemia, The position of the right lateral ventricle was
calculated based on the position of bregma: 0.92 mm poster-
ior to bregma, 1.2 mm lateral to bregma, 3.6 mm below the
skull surface according to the atlas of Paxinos Ga (1998) and
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nist ICI 182,780 and/or vehicle was infused with a Hamilton
syringe (Fisher scientific, Pittsburgh, PA) in a volume of 2 ml
per infusion over 2 min. The injection needle was left in place
for an additional 2 min before being withdrawn. For the
coumestrol peripheral administration, rats received a single
dose of 20 mg diluted in 300 ml of 100% DMSO injected
intracardiaclly one hour before the ischemic insult.
4.7. Histological analysis and hippocampal cell counts
The impact of transient global ischemia on the survival of
hippocampal CA1 pyramidal neurons was examined seven
days after ischemia or sham surgery, rats were killed by
transcardiac perfusion with 4% paraformaldehyde under
deep anesthesia. Brains were rapidly removed. Hematoxiline–
Eosine method was used to stain coronal sections of 25 mm
collected through the entire dorsal hippocampus. Digital
images of every tenth section from each animal (100
sections per brain) were captured and used to trace the
outline of the CA1. Medial, middle and lateral sectors from
the CA1 region of the left and right hippocampus were
photographed at 40X magnification using a Nikon microscope
and digital camera. As previously described by Colbourne and
Corbett (1995) a microscope counting grid (250 mm250 mm)
was positioned a few cells medial from CA2 neurons (lateral
sector), at the apex of the CA1 (middle sector) and the
upswing of CA1 and the number of viable pyramidal neurons
in this 250 mm250 mm region of interest was counted. Viable
neurons had rounded cell bodies and clearly visible nucleoli.
Pyknotic and shrunken neurons were not counted. All cell
counts were carried out by an investigator who was blind to
the animal’s treatment.5. Statistical analysis
Statistical comparison of the number of surviving CA1 pyr-
amidal neurons among groups was performed using a two-
way ANOVA followed by Duncan’s multiple range test for post
hoc analysis. Differences were considered significant at
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